Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients

Atherosclerosis

Volumn 214, Issue 2, 2011, Pages 432-435

  Kappelle, Paul J W H ^a   Lambert, Gilles ^b,c   Dullaart, Robin P F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b HEART RESEARCH INSTITUTE   (Australia)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

Apolipoprotein B; Hyperinsulinemia; Insulin; Proprotein convertase subtilisin kexin type 9; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; GLUCOSE; INSULIN; KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SUBTILISIN; SULFONYLUREA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; ENZYME BLOOD LEVEL; ENZYME IMMUNOASSAY; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN INFUSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ADULT; APOLIPOPROTEINS B; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; INSULIN; MALE; MIDDLE AGED; NETHERLANDS; SERINE ENDOPEPTIDASES; TIME FACTORS; TRIGLYCERIDES;

EID: 79151473645     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.10.028     Document Type: Article

References (21)

1. Horton J.D., Cohen J.C., Hobbs H.H. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009, 50(Suppl.):S172-S177.
2. Lambert G., Charlton F., Rye K.A., Piper D.E. Molecular basis of PCSK9 function. Atherosclerosis 2009, 203:1-7.
3. Abifadel M., Varret M., Rabès J.P., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003, 34:154-156.
4. Cohen J.C., Boerwinkle E., Mosley T.H., Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006, 354:1264-1272.
5. Lambert G., Ancellin N., Charlton F., et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem 2008, 54:1034-1045.
6. Lakoski S.G., Lagace T.A., Cohen J.C., Horton J.D., Hobbs H.H. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009, 94:2537-2543.
7. Baass A., Dubuc G., Tremblay M., et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem 2009, 55:1637-1645.
8. Chan D.C., Lambert G., Barrett P.H., et al. Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism?. Clin Chem 2009, 55:2049-2052.
9. Costet P., Cariou B., Lambert G., et al. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem 2006, 281:6211-6218.
10. Persson L., Gälman C., Angelin B., Rudling M. Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors. Endocrinology 2009, 150:1140-1146.
11. Niesen M., Bedi M., Lopez D. Diabetes alters LDL receptor and PCSK9 expression in rat liver. Arch Biochem Biophys 2008, 470:111-115.
12. Jensen M.D., Heiling V.J. Heated hand vein blood is satisfactory for measurements during free fatty acid kinetic studies. Metabolism 1991, 40:406-409.
13. Demacker P.N., Hijmans A.G., Vos-Janssen H.E., Vańt Laar A., Jansen A.P. A study of the use of polyethylene glycol in estimating cholesterol in high density lipoprotein. Clin Chem 1980, 26:1775-1779.
14. Marsh J.B., Welty F.K., Lichtenstein A.H., Lamon-Fava S., Schaefer E.J. Apolipoprotein B metabolism in humans: studies with stable isotope-labeled amino acid precursors. Atherosclerosis 2002, 162:227-244.
15. Taskinen M.R. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003, 46:733-749.
16. Adiels M., Westerbacka J., Soro-Paavonen A., et al. Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia 2007, 50:2356-2365.
17. Riemens S.C., Sluiter W.J., Dullaart R.P.F. Enhanced escape of non-esterified fatty acids from tissue uptake: its role in impaired insulin-induced lowering of total rate of appearance in obesity and type II diabetes mellitus. Diabetologia 2000, 43:416-426.
18. Chait A., Bierman E.L., Albers J.J. Low-density lipoprotein receptor activity in cultured human skin fibroblasts. Mechanism of insulin-induced stimulation. J Clin Invest 1979, 64:1309-1319.
19. Wade D.P., Knight B.L., Soutar A.K. Hormonal regulation of low-density lipoprotein (LDL) receptor activity in human hepatoma Hep G2 cells. Insulin increases LDL receptor activity and diminishes its suppression by exogenous LDL. Eur J Biochem 1988, 174:213-218.
20. Duvillard L., Florentin E., Lizard G., et al. Cell surface expression of LDL receptor is decreased in type 2 diabetic patients and is normalized by insulin therapy. Diabetes Care 2003, 26:1540-1544.
21. Duvillard L., Pont F., Florentin E., Gambert P., Vergès B. Significant improvement of apolipoprotein B-containing lipoprotein metabolism by insulin treatment in patients with non-insulin-dependent diabetes mellitus. Diabetologia 2000, 43:27-35.